Boardroom Alpha
Boardroom Alpha
PRME · Additional Proxy Materials (DEFA14A) · Filed April 23, 2026

Prime Medicine Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 23, 2026
Ticker
PRME
Accession
0001628280-26-026701
Boardroom Alpha · Filing insights

Prime Medicine's board urges electing Michael Kelly and David Schenkein and ratifying PwC as auditor for 2026.

About Prime Medicine Inc
Market cap
$580M
1Y TSR
+81.4%
3Y TSR
−40.6%
Board grade
D
Sector
Healthcare
CEO
Allan Reine
Last annual meeting: Jun 5, 2026 · View full Prime Medicine Inc profile →
a2026proxycardnotice
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 PRIME MEDICINE, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement if other than Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.


 
Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V90550-P48669 *Please check the meeting materials for any special requirements for meeting attendance. PRIME MEDICINE, INC. 60 FIRST STREET CAMBRIDGE, MA 02141 PRIME MEDICINE, INC. 2026 Annual Meeting Vote by June 4, 2026 11:59 PM ET You invested in PRIME MEDICINE, INC. and it’s time to vote! You have the right to vote on proposals being presented at the 2026 Annual Meeting. Important Notice Regarding the Availability of Proxy Materials for the 2026 Annual Meeting of Stockholders to be Held on June 5, 2026. Vote Virtually at the Meeting* June 5, 2026 2:00 PM ET Virtually at: www.virtualshareholdermeeting.com/PRME2026 Get informed before you vote View the Notice, Proxy Statement and 2025 Annual Report online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2026. If you would like to request a copy of the material(s) for this and/or future annual stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 (toll-free from the U.S., U.S. territories and Canada) or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.


 
Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V90551-P48669 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming 2026 Annual Meeting. Please follow the instructions on the reverse side to vote these important matters. 1. To elect Michael Kelly and David Schenkein, M.D. as Class I Directors. For Nominees: 01) Michael Kelly 02) David Schenkein, M.D. 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For NOTE: Such other business as may properly come before the meeting or any continuations, adjournments, and postponements thereof.


 
From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Prime Medicine Inc (PRME)

Reference

Frequently asked questions

When did Prime Medicine Inc file this DEFA14A?
Prime Medicine Inc (PRME) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 23, 2026. The accession number assigned by EDGAR is 0001628280-26-026701.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Prime Medicine's board urges electing Michael Kelly and David Schenkein and ratifying PwC as auditor for 2026. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Prime Medicine Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Prime Medicine Inc has filed under CIK 1894562, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer